Jill Drake - Concepedia

Concepedia

Author

Jill Drake

University of Otago

Also Known As

J Drake, J M Drake, J Michael Drake, J. DRAKE, J. Drake, J. Michael Drake, JILL DRAKE, Jill Drake, Jill M. Drake, Judith Drake

46

Publications

1.5K

Citations

19

H-Index

40

Concepts

All Affiliations

University of Otago Christchurch Hospital University of Auckland Canterbury Health Laboratories Dunedin Public Hospital

JD

About

Jill Drake is an author at University of Otago specializing in medicine, pharmacology, and pharmacotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	6	6	315
2	Natural Sciences	1	1	11
3	Public Health	1	1	153
4	Biochemistry	1	1	11
5	Health Policy	1	1	153

Jill Drake

×

26

Publications

1.5K

Citations

19

H-Index

	Year	Citations
Starting dose is a risk factor for allopurinol hypersensitivity syndrome: A proposed safe starting dose of allopurinol Lisa K. Stamp, William J. Taylor, Peter B. Jones, Arthritis & Rheumatism	2012	285
Treatment persistence with once-monthly ibandronate and patient support vs. once-weekly alendronate: results from the PERSIST study* Alun Cooper, Jill Drake, E. Brankin International Journal of Clinical Practice OsteopathyIbandronate/psp GroupPharmacotherapyOral BisphosphonatesOsteoporosis	2006	153
A randomised controlled trial of the efficacy and safety of allopurinol dose escalation to achieve target serum urate in people with gout Lisa K. Stamp, Peter T. Chapman, Murray L. Barclay, Annals of the Rheumatic Diseases	2017	145
Effects of Allopurinol Dose Escalation on Bone Erosion and Urate Volume in Gout: A Dual‐Energy Computed Tomography Imaging Study Within a Randomized, Controlled Trial Nicola Dalbeth, Karen Billington, Anthony Doyle, Arthritis & Rheumatology	2019	96
ABCG2 loss-of-function polymorphism predicts poor response to allopurinol in patients with gout R.L. Roberts, M C Wallace, Amanda Phipps‐Green, The Pharmacogenomics Journal UrologyAutoimmune DiseaseGouty ArthritisHuman PolymorphismAbcg2 Loss-of-function Polymorphism	2016	91
Clinically Insignificant Effect of Supplemental Vitamin C on Serum Urate in Patients With Gout: A Pilot Randomized Controlled Trial Lisa K. Stamp, J O'donnell, Christopher Frampton, Arthritis & Rheumatism	2013	87
Allopurinol dose escalation to achieve serum urate below 6 mg/dL: an open-label extension study Lisa K. Stamp, Peter T. Chapman, Murray L. Barclay, Annals of the Rheumatic Diseases	2017	77
Relationship Between Serum Urate and Plasma Oxypurinol in the Management of Gout: Determination of Minimum Plasma Oxypurinol Concentration to Achieve a Target Serum Urate Level Lisa K. Stamp, Murray L. Barclay, J O'donnell, Clinical Pharmacology & Therapeutics	2011	60
Effects of Changing from Oral to Subcutaneous Methotrexate on Red Blood Cell Methotrexate Polyglutamate Concentrations and Disease Activity in Patients with Rheumatoid Arthritis Lisa K. Stamp, Murray L. Barclay, J O'donnell, The Journal of Rheumatology	2011	60
Myeloperoxidase and oxidation of uric acid in gout: implications for the clinical consequences of hyperuricaemia Lisa K. Stamp, Rufus Turner, Irada Khalilova, Lara D. Veeken	2014	52

Page 1